{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-090748","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2026-08-17T20:05:47+00:00","discovered_at":"2026-08-17T20:07:01.348768+00:00","generated_at":"2026-08-17T20:07:44.086854+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Silo Pharma shareholders approve 37.5x increase in authorized shares to 250M","bullets":["Shareholders approved increase in authorized common stock from 6,666,667 to 250,000,000 shares on Aug 14, 2026.","Vote: 498,224 for, 190,599 against, 8,485 abstain; no broker non-votes.","Directors re-elected: Eric Weisblum, Wayne Linsley, Kevin Munoz, Jeff Pavell; each received ~359k for votes.","Ratified Salberg & Company as independent auditor for FY2026; 690,743 for, 2,571 against.","Adjournment proposal approved 556,797 for, 131,873 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-090748","json":"https://secwatch.observer/filing/0001213900-26-090748.json","markdown":"https://secwatch.observer/filing/0001213900-26-090748.md","text":"https://secwatch.observer/filing/0001213900-26-090748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026090748/0001213900-26-090748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026090748/ea0302240-8k_silo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T20:07:44.086854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}